Despite the success of RTK inhibitors, challenges remain. Resistance to RTK-targeted therapies can develop through various mechanisms, such as secondary mutations in the kinase domain, activation of alternative signaling pathways, and phenotypic changes in cancer cells. Understanding these mechanisms is crucial for developing next-generation inhibitors and combination therapies.
